References
- 1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34:1589-96.10.1097/01.CCM.0000217961.75225.E9
- 2. Dellinger RP, Levy MM, Carlet JM, Surviving Sepsis Campaign Management Guidelines Committee. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36:296-327.10.1097/01.CCM.0000298158.12101.41
- 3. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J ClinMicrobiol Infect Dis. 2004; 23:163-7.10.1007/s10096-003-1084-2
- 4. Rodriguez-Bano J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajad JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897-902.10.1001/archinte.168.17.1897
- 5. Mirelis B, Navarro F, Miro E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum betalactamase. Emerg Infect Dis. 2003; 9:1024-5.10.3201/eid0908.030094
- 6. Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtaș M, Gürcüoglu E, et al. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother. 2008; 20:581-5.10.1179/joc.2008.20.5.581
- 7. Ling TK, Xiong J, Yu Y, Lee CC, Ye H, Hawkey PM. Multicenter antimicrobial susceptibility survey ofgram-negative bacteria isolated from patients with community-acquired infections in the People’s Republic of China. Antimicrob Agents Chemother. 2006; 50:41-67.
- 8. Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis. 2008; 27:85-8.10.1007/s10096-007-0401-6
- 9. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control. 2007; 35:606-12.10.1016/j.ajic.2007.05.008
- 10. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000; 31(Suppl 4):S131-810.1086/314079
- 11. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcome in the ICU setting. Chest. 2000; 118:146-55.10.1378/chest.118.1.146
- 12. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007; 55:254-9.10.1016/j.jinf.2007.04.007
- 13. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001; 32:1162-71.10.1086/319757
- 14. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia:Churchill Livingston; 2009, p. 957-85.
- 15. Donowitz GR. Pleuropulmonary and bronchial infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingston; 2009, p. 891-916.
- 16. Sifri CD, Madoff LC. Intra-abdominal infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia:Churchill Livingston; 2009, p. 1035-44.
- 17. Pasternack MS, Swartz MN. Skin and soft tissue infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingston; 2009, p. 1289-312.
- 18. CLSI (NCCLS). Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, M100-S18. Vol. 28. Wayne:Clinical Laboratory Standards Institute; 2008.
- 19. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996; 48:907-16.10.1016/0895-4356(96)00025-X
- 20. Chayakulkeeree M, Junsriwong P, Keerasuntonpong A, Tribuddharat C, Thamlikitkul V. Epidemiology of extended-spectrum beta-lactamaseproducing gramnegative bacilli at Siriraj Hospital, Thailand, 2003. Southeast Asian J Trop Med Public Health. 2005; 36:1503-9.
- 21. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Predictors of mortality among patients with community-onset infection due to extended-spectrum beta-lactamase-producing Escherichia coli in Thailand. Infect Control Hosp Epidemiol. 2008;29:80-2.
- 22. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31-7.10.1086/420816
- 23. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentn C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682-90.10.1086/604713
- 24. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006; 57:780-3.
- 25. Martinez JA, Aguilar J, Almela M, Marco F, Soriano A, López F, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum betalactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother. 2006;58:1082-5.
- 26. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137:791-7.10.7326/0003-4819-137-10-200211190-00007
- 27. Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruíz M, Peña C, et al. Spanish network for research in infectious diseases (REIPI). Community-onset bacteremia due to extended-spectrum beta-lactamaseproducing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010; 50:40-8.10.1086/649537
- 28. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001; 32:1055-61.10.1086/319600
- 29. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002; 34:1558-63.10.1086/340533
- 30. Behar PR, Teixeira PJ, Fachel JM, Kalil AC. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamaseproducing Klebsiella pneumoniae infections. A prospective controlled study. J Hosp Infect. 2008; 68:123-9.10.1016/j.jhin.2007.10.022
- 31. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterialcystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999; 29:745-58.10.1086/520427
- 32. Dow G, Rao P, Harding G, Brunka J, Kennedy J, Alfa M, et al. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis. 2004; 39:658-64.10.1086/423000
- 33. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiellapneumoniae isolates causing bacteremia. Clin Infect Dis. 2000; 30:473-8.10.1086/313719
- 34. Oktem IM, Gulay Z, Bicmen M, Gur D. HITIT Project Study Group. qnrA prevalence in extended-spectrum beta-lactamase-positive Enterobacteriaceae isolates from Turkey. Jpn J Infect Dis. 2008; 61:13-7.
- 35. LavillaS, Gonzalez-Lopez JJ, Sabate M, Garcia-Fernandez A, Larrosa MN, Bartolome RM, et al. Prevalence of qnr genes among extended-spectrum beta-lactamase-producing enterobacterial isolates in Barcelona, Spain. J Antimicrob Chemother. 2008; 61:291-5.